Skip to main content
SpringerLink
Log in

Vakzination und Immunchemotherapie zur adjuvanten oder palliativen Therapie des fortgeschrittenen Nierenzellkarzinoms: Stand der Evidenz im März 2004

  • Chapter
Pharmakotherapie in der Urologie

  • 739 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Atzpodien J, Hoffmann R, Franzke M, Stief C, Wandert T, Reitz M (2002) thirteen-year, long-term efficacy of interferon 2a and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 95: 1045–1050

    Article  PubMed  Google Scholar 

  2. Atzpodien J, Kirchner H, Jonas U et al. (2004) Interleukin-2-and interferon α-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the german cooperative renal carcinoma chemoimmunotherapy group (DGCIN). J Clin Oncol 22: DOI 10.1200/JCO.2004.06.155

    Google Scholar 

  3. Clark J, Atkins MV, Urba W et al. (2003) for the Cytokine Working Group. Adjuvant high-dose bolus interleuin-2 (HD IL-2) for patients (pts.) with high-risk renal cell carcinoma (RCC). A Cytokine Working Group randomized trial. Proc ASCO 2003: abstr. 659

    Google Scholar 

  4. Coppin C, Porzsolt F, Kumpf J, Coldman A, Wilt T (2001) Immunotherapy for advanced renal cell cancer (Cochrane Review). In: The Cochrane Library, vol 1, 2001. Oxford: Update Software

    Google Scholar 

  5. Coppin C, Forzsolt F (2003) Kidney cancer. In: Mason M. (ed) Treating tumours of the urogenital system, section VI, chapter 30: pp 333–345

    Google Scholar 

  6. Flanigan RC, Salmon S, Blumenstein BA (2001) Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655–1659

    Article  PubMed  Google Scholar 

  7. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Poppel H van, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: combined analysis. J Urol 171: 1071–1076

    PubMed  Google Scholar 

  8. Fossa SD, Marinelli G, Otto U et al. (1992) Recombinant interferon α-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 3: 301–305

    PubMed  Google Scholar 

  9. Hancock B, Griffiths G, Ritchie A et al. (2000) Updated results of the MRC randomised controlled trial of α-interferon vs. MPA in patients with metastatic renal carcinoma. Proc ASCO 2000: abstr. 1336

    Google Scholar 

  10. Höltl L, Zelle-Rieser C, Gander J et al. (2002) Immunotheapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8: 3369–3376

    PubMed  Google Scholar 

  11. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrezewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Doehn C (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363: 594–599

    Article  PubMed  Google Scholar 

  12. Märten A, Flieger D, Renoth S et al. (2002) Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immuno Immunother 51: 637–644

    Article  Google Scholar 

  13. Messing EM, Manola J, Wilding G et al. (2003) Phase III study of interferon α-NL as adjuvant treatment for respectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21: 1214–1222

    Article  PubMed  Google Scholar 

  14. Mickisch GH, Farin A, Poppel H van, Prijck L de, Sylvester R (2001) EORTC Genitourinary Group: Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966–970

    Article  PubMed  Google Scholar 

  15. Müller MR, Wierecky J, Brugger W, Gouttefangeas C, Kanz L, Brossart P (2003) Vaccinations with peptide pulsed dendritic cells induces clinical and immunological responses in patients with metastativ enal cell carcinoma. Proc ASCO 2003: abstr. 672

    Google Scholar 

  16. Négrier S, Escudier B, Lasset C et al. (1996) The FNCLCC CRECY Trial: Interleukin-2 (IL2) + interferon (IFN) is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC). Proc ASCO 1996: 248 (abstr. 629)

    Google Scholar 

  17. Négrier S, Escudier B, Lasset C et al. (1998) Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. New Engl J Med 338: 1272–1278

    Article  PubMed  Google Scholar 

  18. Négrier S, Douillard J-Y, Lasset C, Chevreau C, Ravaid A, Philip T, Escudier B (2000a) Cytokine treatment for metastatic renal carcinoma — The experience of the Groupe Francais d'Immunotherapie. Electr J Oncol 1: 28–33

    Google Scholar 

  19. Négrier S, Caty A, Lesimple T et al. (2000b) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon α with or without fluorouracil. J Clin Oncol 18: 4009–4015

    PubMed  Google Scholar 

  20. Negrier S (2004) Better survival with IL-2 based regimens? Possibly only in highly selected patients. J Clin Oncol 23.2.2004 (ahead of print Vol 22 (7), 1st April 2004): 10.1200/JCO 2004.01.998

    Google Scholar 

  21. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I et al. (2002) Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 25: 500–508

    Article  PubMed  Google Scholar 

  22. Pyrhönen S, Salminen E, Lehtonen T et al. (1996) Recombinant interferon α-2a with vinblastine vs. vinblastine alone in advanced renal cell carcinoma. A phase III study. Proc ASCO 244 (abstr. 614)

    Google Scholar 

  23. Pyrhönen S, Slaminen E, Ruutu M et al. (1999) Prospective randomized trial of interferon α-2a plus vinblastine vs. vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859–2867

    PubMed  Google Scholar 

  24. Ritchie et members of MRC (1999) Interferon-α and survival in metastatic renal cell carcinoma: early results of a randomized controlled trial. Lancet 353: 14–17

    Google Scholar 

  25. Yang JC, Haworth L, Sherry RM et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. NEJM 349: 427–434

    Article  PubMed  Google Scholar 

  26. Yang JC, Sherry RM, Steinberg SM et al. (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21: 3127–3132

    Article  PubMed  Google Scholar 

Download references

Authors
  1. D. Rohde
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Rohde, D. (2005). Vakzination und Immunchemotherapie zur adjuvanten oder palliativen Therapie des fortgeschrittenen Nierenzellkarzinoms: Stand der Evidenz im März 2004. In: Pharmakotherapie in der Urologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26450-7_5

Download citation

  • DOI: https://doi.org/10.1007/3-540-26450-7_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-23449-4

  • Online ISBN: 978-3-540-26450-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation